Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04263727 · ClinicalTrials.gov registry record
A Study of Patients With Chronic Disease
A clinical trial, sponsored by Target PharmaSolutions.
- Terminated
- Registry status
- 579
- Enrollment target
NCT04263727: Clinical Trial study, sponsored by Target PharmaSolutions.
NCT04263727 is a clinical trial that was terminated before completion, run by Target PharmaSolutions. The registered enrollment target is 579 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04263727 was terminated before completion, sponsored by Target PharmaSolutions.
- TERMINATED
- Registry status
- 579 participants
- Enrollment target
Study Summary
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2024-11-21 |
Why NCT04263727 stopped before completion
NCT04263727 is an observational study that tracks outcomes without assigning an intervention. The registered 579 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04263727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04263727 about?
NCT04263727 is a clinical study titled "A Study of Patients With Chronic Disease". TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared stu...
What is the current status of trial NCT04263727?
This trial is currently terminated. The enrollment target is 579 participants. The study started on 2020-02-27. Estimated completion is 2024-11-21.
Who is sponsoring clinical trial NCT04263727?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI